University of Kentucky Markey Cancer Center - Cancer Center Support Grant

项目总结/摘要 马基癌症中心（MCC）成立于35年前，是一个以大学为基础的矩阵。 肯塔基州（英国）大学的癌症中心，肯塔基州的旗舰高等教育机构。MCC是 唯一的国家癌症研究所（NCI）指定的癌症中心在肯塔基州，一个440万的国家，导致 全国各地的癌症发病率和死亡率，并作为MCC的集水区。超过3.47亿美元， 自世纪挑战中心主任B博士受聘以来，国家、机构和慈善投资。马克·埃弗斯（CS）在 2009年支持了重大的研究和资源扩展，使大量的新教师 招聘，项目开发，临床和共享资源空间的改造，以及新的最先进的 仪器，以及全州的教育和社区推广工作。119名MCC成员 来自8所英国学院的28个系，自2013年以来招募了28名新教师。癌症相关研究 MCC调查人员的年度总费用超过3870万美元，自2012年以来增加了1030万美元。超过 在过去4年中，9，357例受试者参与了干预性试验。已发表851篇 自2013年以来以癌症为重点的出版物，其中28%为计划内出版物，16%为计划间出版物，58%为计划外出版物。 机构间合作。研究在4个MCC研究项目中进行：癌细胞 生物学和信号传导;癌症预防和控制;药物发现、递送和转化 治疗学;基因组不稳定性、表观遗传学和代谢。5个共享资源设施（SRF） 通过为专业知识和先进的技术提供强大的基础设施， 方法：生物标本获取和转化病理学;生物统计学和生物信息学;癌症 研究信息学;流式细胞术和细胞分选;和氧化还原代谢。两个新的SRF（行为 和基于社区的研究和癌基因组学）正在开发中。重大成就包括： 开发一个由NCI赞助的早期治疗计划，包括一个活跃的分子肿瘤委员会， 精准医学中心;将MCC网络从8个站点扩大到24个站点;建立区域 代谢组学中心（U24）;授予2个新的癌症相关中心-生物医学研究中心 卓越（COBRE）在癌症和代谢和阿巴拉契亚环境研究中心 科学;以及在全州范围内扩大社区外联/教育举措。MCC研究重点 关于肯塔基州最严重的癌症负担，重点是“痛苦的”阿巴拉契亚肯塔基州地区， 那里的癌症发病率和死亡率超过了整个州MCC带来了独特的基础， 临床和人口研究的优势，这一使命。这些优势是所有MCC计划的组成部分 并共同提供强大的能力，为重要的 这将有助于国家通过发现癌症来战胜癌症的努力 临床翻译、癌症预防和社区外展。

PROJECT SUMMARY/ABSTRACT The Markey Cancer Center (MCC) was established more than 35 years ago as a university-based matrix cancer center at the University of Kentucky (UK), Kentucky's flagship institution of higher education. MCC is the only National Cancer Institute (NCI)-designated Cancer Center in Kentucky, a state of 4.4 million that leads the nation for all-site cancer incidence and mortality and serves as the MCC's catchment area. Over $347M in state, institutional, and philanthropic investment since recruitment of MCC Director Dr. B. Mark Evers (CS) in 2009 have supported significant research and resource expansion, enabling substantial new faculty recruitment, program development, renovation of clinical and shared resource space, and new state-of-the art instrumentation, as well as statewide education and community outreach efforts. The 119 MCC members draw from 28 departments in 8 UK colleges, with 28 new faculty recruited since 2013. Cancer-relevant research funding to MCC investigators exceeds $38.7M in total annual costs, an increase of $10.3M since 2012. Over the last 4 years, 9,357 subjects have been accrued to interventional trials. Members have published 851 cancer-focused publications since 2013, reflecting 28% intra-programmatic, 16% inter-programmatic, and 58% inter-institutional collaborations. Research is conducted within 4 MCC Research Programs: Cancer Cell Biology and Signaling; Cancer Prevention and Control; Drug Discovery, Delivery and Translational Therapeutics; and Genomic Instability, Epigenetics and Metabolism. Five Shared Resource Facilities (SRFs) facilitate cutting-edge research by providing robust infrastructure for specialized expertise and advanced methods: Biospecimen Procurement and Translational Pathology; Biostatistics and Bioinformatics; Cancer Research Informatics; Flow Cytometry and Cell Sorting; and Redox Metabolism. Two new SRFs (Behavioral and Community-Based Research and Oncogenomics) are in development. Significant achievements include: development of an NCI-sponsored early therapeutics program, including an active Molecular Tumor Board and Precision Medicine Center; expansion of the MCC Network from 8 to 24 sites; establishment of a regional Metabolomics Center (U24); award of 2 new cancer-related centers – a Center of Biomedical Research Excellence (COBRE) in Cancer and Metabolism and a Center for Appalachian Research in Environmental Sciences; and expansion of community outreach/education initiatives across the state. MCC research focuses on Kentucky's most serious cancer burdens with emphasis on the “distressed” Appalachian Kentucky region, where cancer incidence and mortality rates surpass those for the entire state. The MCC brings unique basic, clinical, and population research strengths to this mission. These strengths are integral to all MCC programs and collectively provide robust capacity to deliver transformative interventional research to an important underserved priority population, thereby contributing to national efforts to conquer cancer through discovery and clinical translation, cancer prevention, and community outreach.